Human papillomavirus vaccinations at recommended ages: How a middle school-based educational and vaccination program increased uptake in the Rio Grande Valley

Human papillomavirus (HPV) vaccination is recommended for U.S. adolescents at ages 11–12 requiring two or three doses depending on if the vaccine series started before age 15. The objective was to compare HPV vaccination rates among medically underserved, economically disadvantaged, students in rura...

Full description

Bibliographic Details
Main Authors: Ana M. Rodriguez, Thuy Quynh N. Do, Lu Chen, Kathleen M. Schmeler, Jane R. Montealegre, Yong-Fang Kuo
Format: Article
Language:English
Published: Taylor & Francis Group 2022-11-01
Series:Human Vaccines & Immunotherapeutics
Subjects:
Online Access:http://dx.doi.org/10.1080/21645515.2022.2133315
_version_ 1797673080799100928
author Ana M. Rodriguez
Thuy Quynh N. Do
Lu Chen
Kathleen M. Schmeler
Jane R. Montealegre
Yong-Fang Kuo
author_facet Ana M. Rodriguez
Thuy Quynh N. Do
Lu Chen
Kathleen M. Schmeler
Jane R. Montealegre
Yong-Fang Kuo
author_sort Ana M. Rodriguez
collection DOAJ
description Human papillomavirus (HPV) vaccination is recommended for U.S. adolescents at ages 11–12 requiring two or three doses depending on if the vaccine series started before age 15. The objective was to compare HPV vaccination rates among medically underserved, economically disadvantaged, students in rural middle school districts (Rio Grande Valley [RGV], Texas) by age of initiation (≤ age 11 years vs. age 12 years and older). This quasi-experimental study included 1,766 students (884 females; 882 males) who received at least one HPV vaccine dose through our school-based vaccination program between 08/2016-06/2022. Summary statistics were stratified by age at initiation and gender. The overall HPV up-to-date (UTD) rate was 59.7% (95% Confidence Interval: 57.4–62.0%). The median age at HPV UTD (range) was 12 years (9–19) and median interval between HPV vaccine doses (range) was 316 days (150–2,855). Most students received the HPV vaccine bundled with other vaccinations (72.4%, 1,279/1,766). There was a higher HPV UTD rate among students who initiated the HPV vaccine on or before age 11 than those who initiated on or after age 12 (73.6% versus 45.1%, respectively). The median age of HPV UTD was age 12 for those initiating on or before 11 years versus age 13 for those initiating on or after 12 years of age. Initiating the HPV vaccine at age ≤11 years increased completion of the HPV vaccine series. Improving HPV vaccine coverage and introduction of pan-gender vaccination programs will significantly decrease HPV-related diseases in the RGV.
first_indexed 2024-03-11T21:40:21Z
format Article
id doaj.art-091d1d013f494c29ab3004ef825156cf
institution Directory Open Access Journal
issn 2164-5515
2164-554X
language English
last_indexed 2024-03-11T21:40:21Z
publishDate 2022-11-01
publisher Taylor & Francis Group
record_format Article
series Human Vaccines & Immunotherapeutics
spelling doaj.art-091d1d013f494c29ab3004ef825156cf2023-09-26T13:19:10ZengTaylor & Francis GroupHuman Vaccines & Immunotherapeutics2164-55152164-554X2022-11-0118610.1080/21645515.2022.21333152133315Human papillomavirus vaccinations at recommended ages: How a middle school-based educational and vaccination program increased uptake in the Rio Grande ValleyAna M. Rodriguez0Thuy Quynh N. Do1Lu Chen2Kathleen M. Schmeler3Jane R. Montealegre4Yong-Fang Kuo5University of Texas Medical BranchUniversity of Texas Medical BranchUniversity of Texas Medical BranchThe University of Texas MD Anderson Cancer CenterBaylor College of MedicineUniversity of Texas Medical BranchHuman papillomavirus (HPV) vaccination is recommended for U.S. adolescents at ages 11–12 requiring two or three doses depending on if the vaccine series started before age 15. The objective was to compare HPV vaccination rates among medically underserved, economically disadvantaged, students in rural middle school districts (Rio Grande Valley [RGV], Texas) by age of initiation (≤ age 11 years vs. age 12 years and older). This quasi-experimental study included 1,766 students (884 females; 882 males) who received at least one HPV vaccine dose through our school-based vaccination program between 08/2016-06/2022. Summary statistics were stratified by age at initiation and gender. The overall HPV up-to-date (UTD) rate was 59.7% (95% Confidence Interval: 57.4–62.0%). The median age at HPV UTD (range) was 12 years (9–19) and median interval between HPV vaccine doses (range) was 316 days (150–2,855). Most students received the HPV vaccine bundled with other vaccinations (72.4%, 1,279/1,766). There was a higher HPV UTD rate among students who initiated the HPV vaccine on or before age 11 than those who initiated on or after age 12 (73.6% versus 45.1%, respectively). The median age of HPV UTD was age 12 for those initiating on or before 11 years versus age 13 for those initiating on or after 12 years of age. Initiating the HPV vaccine at age ≤11 years increased completion of the HPV vaccine series. Improving HPV vaccine coverage and introduction of pan-gender vaccination programs will significantly decrease HPV-related diseases in the RGV.http://dx.doi.org/10.1080/21645515.2022.2133315human papillomavirus vaccineadolescent healthhuman papillomavirus-related cancers and diseasesschool-based vaccinationprovider recommendationrio grande valley
spellingShingle Ana M. Rodriguez
Thuy Quynh N. Do
Lu Chen
Kathleen M. Schmeler
Jane R. Montealegre
Yong-Fang Kuo
Human papillomavirus vaccinations at recommended ages: How a middle school-based educational and vaccination program increased uptake in the Rio Grande Valley
Human Vaccines & Immunotherapeutics
human papillomavirus vaccine
adolescent health
human papillomavirus-related cancers and diseases
school-based vaccination
provider recommendation
rio grande valley
title Human papillomavirus vaccinations at recommended ages: How a middle school-based educational and vaccination program increased uptake in the Rio Grande Valley
title_full Human papillomavirus vaccinations at recommended ages: How a middle school-based educational and vaccination program increased uptake in the Rio Grande Valley
title_fullStr Human papillomavirus vaccinations at recommended ages: How a middle school-based educational and vaccination program increased uptake in the Rio Grande Valley
title_full_unstemmed Human papillomavirus vaccinations at recommended ages: How a middle school-based educational and vaccination program increased uptake in the Rio Grande Valley
title_short Human papillomavirus vaccinations at recommended ages: How a middle school-based educational and vaccination program increased uptake in the Rio Grande Valley
title_sort human papillomavirus vaccinations at recommended ages how a middle school based educational and vaccination program increased uptake in the rio grande valley
topic human papillomavirus vaccine
adolescent health
human papillomavirus-related cancers and diseases
school-based vaccination
provider recommendation
rio grande valley
url http://dx.doi.org/10.1080/21645515.2022.2133315
work_keys_str_mv AT anamrodriguez humanpapillomavirusvaccinationsatrecommendedageshowamiddleschoolbasededucationalandvaccinationprogramincreaseduptakeintheriograndevalley
AT thuyquynhndo humanpapillomavirusvaccinationsatrecommendedageshowamiddleschoolbasededucationalandvaccinationprogramincreaseduptakeintheriograndevalley
AT luchen humanpapillomavirusvaccinationsatrecommendedageshowamiddleschoolbasededucationalandvaccinationprogramincreaseduptakeintheriograndevalley
AT kathleenmschmeler humanpapillomavirusvaccinationsatrecommendedageshowamiddleschoolbasededucationalandvaccinationprogramincreaseduptakeintheriograndevalley
AT janermontealegre humanpapillomavirusvaccinationsatrecommendedageshowamiddleschoolbasededucationalandvaccinationprogramincreaseduptakeintheriograndevalley
AT yongfangkuo humanpapillomavirusvaccinationsatrecommendedageshowamiddleschoolbasededucationalandvaccinationprogramincreaseduptakeintheriograndevalley